<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-144777" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dupilumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gade</surname>
            <given-names>Anita</given-names>
          </name>
          <aff>Stamford Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ghani</surname>
            <given-names>Hira</given-names>
          </name>
          <aff>NYIT College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rubenstein </surname>
            <given-names>Richard</given-names>
          </name>
          <aff>Medical College of Virginia, Richmond, VA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anita Gade declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hira Ghani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richard Rubenstein declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-144777.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Dupilumab is an injectable prescription medication administered subcutaneously to treat severe and refractory forms of atopic dermatitis.&#x000a0;The US Food and Drug Administration (FDA) approved the medication in April 2017 to treat moderate-to-severe, resistant, atopic dermatitis unresponsive to conventional therapy, including topical corticosteroids.&#x000a0;Dupilumab is also used as a maintenance treatment for asthma and chronic rhinosinusitis with nasal polyposis in adults and children, in conjunction with other medications.</p>
        <p>Dupilumab is also now FDA-approved for prurigo nodularis and eosinophilic esophagitis. Non-FDA-approved indications include allergic contact dermatitis, hand dermatitis, chronic spontaneous urticaria, and alopecia areata. Extensive literature suggests the efficacy of dupilumab in treating conditions characterized by Th2-mediated inflammation. Clinical trials are currently in the pipeline to explore the potential of dupilumab in treating autoimmune blistering diseases, such as bullous pemphigoid. This activity describes dupilumab, including its mechanism of action, adverse event and safety profiles, eligible patient populations, and contraindications. It also highlights the interprofessional team's role in managing patients on dupilumab treatment.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Apply evidence-based guidelines and data to guide dupilumab treatment decisions in clinical practice.</p></list-item><list-item><p>Identify the appropriate indications for dupilumab in the treatment of moderate-to-severe atopic dermatitis.</p></list-item><list-item><p>Assess&#x000a0;the treatment response and monitor for adverse effects during dupilumab therapy.</p></list-item><list-item><p>Implement effective collaboration among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from dupilumab.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144777&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144777">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-144777.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Dupilumab is a human monoclonal antibody administered subcutaneously to inhibit the interleukin-4 receptor subunit &#x003b1; (IL-4R &#x003b1;). The US Food and Drug Administration (FDA) approved dupilumab in April 2017 for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and pediatric patients aged&#x000a0;6 and older, as well as for chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults.<xref ref-type="bibr" rid="article-144777.r1">[1]</xref>&#x000a0;Since the incidence of&#x000a0;atopic dermatitis has been rising, especially in the developed and industrialized parts of the world, dermatologists must prescribe treatment regimens that are both effective and safe to use in the long-term management of this chronic skin condition.<xref ref-type="bibr" rid="article-144777.r2">[2]</xref>&#x000a0;Dupilumab is also used in treating adults with atopic dermatitis symptoms inadequately controlled with topical corticosteroid use.<xref ref-type="bibr" rid="article-144777.r3">[3]</xref><xref ref-type="bibr" rid="article-144777.r4">[4]</xref>&#x000a0;Currently, no specific guidelines deem the drug safe for children&#x000a0;younger than 6.<xref ref-type="bibr" rid="article-144777.r4">[4]</xref><xref ref-type="bibr" rid="article-144777.r5">[5]</xref></p>
        <p>Dupilumab has been shown to enhance lung function and decrease severe exacerbations in patients with uncontrolled persistent asthma, irrespective of baseline eosinophil count, and when used in addition to inhaled corticosteroids (ICS) and long-acting &#x003b2;-2 agonists (LABA), as compared to standard asthma therapy.<xref ref-type="bibr" rid="article-144777.r6">[6]</xref><xref ref-type="bibr" rid="article-144777.r7">[7]</xref>&#x000a0;The American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines recommend using dupilumab as an additional treatment option for patients with severe eosinophilic asthma or dependence on oral corticosteroids.<xref ref-type="bibr" rid="article-144777.r8">[8]</xref></p>
        <p>In 2022, dupilumab became the first treatment to receive FDA approval for prurigo nodularis (PN) in adults.<xref ref-type="bibr" rid="article-144777.r9">[9]</xref><xref ref-type="bibr" rid="article-144777.r10">[10]</xref>&#x000a0;Dupilumab is also the first biologic approved by the FDA for eosinophilic esophagitis in children older than 12.<xref ref-type="bibr" rid="article-144777.r11">[11]</xref><xref ref-type="bibr" rid="article-144777.r12">[12]</xref>&#x000a0;Dupilumab is recommended for treating eosinophilic esophagitis by the American Academy of Allergy, Asthma, and Immunology and the American Gastroenterological Association.<xref ref-type="bibr" rid="article-144777.r13">[13]</xref></p>
        <p>
<bold>Non-FDA Approved Indications</bold>
</p>
        <p>Non-FDA-approved indications include allergic contact dermatitis, hand dermatitis, chronic spontaneous urticaria, and alopecia areata.<xref ref-type="bibr" rid="article-144777.r1">[1]</xref><xref ref-type="bibr" rid="article-144777.r14">[14]</xref>&#x000a0;Extensive literature suggests the efficacy of dupilumab in treating conditions characterized by Th2-mediated inflammation.<xref ref-type="bibr" rid="article-144777.r15">[15]</xref>&#x000a0;Clinical investigations are currently being conducted to assess the effectiveness of dupilumab in treating autoimmune blistering diseases, including bullous pemphigoid and chronic obstructive pulmonary disease.<xref ref-type="bibr" rid="article-144777.r16">[16]</xref><xref ref-type="bibr" rid="article-144777.r17">[17]</xref></p>
      </sec>
      <sec id="article-144777.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass designed to inhibit receptor signaling downstream of the JAK-STAT pathway by blocking interleukin-4/interleukin-13 (IL-4/IL-13) receptors.<xref ref-type="bibr" rid="article-144777.r4">[4]</xref>&#x000a0;As an IL-4R&#x003b1; antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, or interleukins, that induce inflammatory and immunological responses in several conditions, including eczema, asthma, allergic reactions, and rhinosinusitis.<xref ref-type="bibr" rid="article-144777.r18">[18]</xref> Essentially, IL-4R&#x003b1; is a component common to both IL-4 and IL-13 receptor complexes and is ubiquitously expressed in innate and adaptive immune cells to promote the signaling of IL-4 and IL-13.<xref ref-type="bibr" rid="article-144777.r19">[19]</xref><xref ref-type="bibr" rid="article-144777.r20">[20]</xref>&#x000a0;By blocking this pathway, dupilumab affects&#x000a0;3 integral disease mechanisms of atopic dermatitis: the decrease of skin barrier function, the class switch to IgE, and the Th2 differentiation.<xref ref-type="bibr" rid="article-144777.r4">[4]</xref><xref ref-type="bibr" rid="article-144777.r21">[21]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Following a subcutaneous (SC) dose of dupilumab, the peak plasma concentration (Cmax) is typically achieved about&#x000a0;1 week after the dose. In most clinical trials, the steady-state concentrations were reached by week 16.<xref ref-type="bibr" rid="article-144777.r22">[22]</xref>&#x000a0;The bioavailability of dupilumab is similar among patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis (EoE), and peanut allergy after a SC dose, ranging from 61% to 64%.&#x000a0;</p>
        <p><bold>Distribution:</bold> The estimated total volume of distribution is approximately 4.8&#x000b1;1.3 L.</p>
        <p><bold>Metabolism:</bold> The metabolic pathway of dupilumab remains uncharacterized. However, given it is a human monoclonal IgG4 antibody,&#x000a0; dupilumab is expected to undergo degradation into peptides and amino acids via catabolic pathways, similar to the endogenous IgG.<xref ref-type="bibr" rid="article-144777.r23">[23]</xref></p>
        <p><bold>Excretion:</bold> After administering different steady-state doses of dupilumab, the median time for non-detectable concentration ranges from 9 to 13 weeks in pediatric patients (12 to 17 years) and adults. According to population pharmacokinetic studies, the median duration for plasma concentration to become non-detectable is roughly 1.5 times higher (up to 19 weeks) in pediatric subjects 6 to 11 years and 2.5 times higher (up to 32 weeks) in pediatric subjects aged 6 months to 5 years compared to adults. Age does not impact dupilumab clearance in adults and pediatric subjects aged 6 to 17. However, the clearance of dupilumab increases in pediatric subjects aged 6 months to 5 years. The emergence of antibodies against dupilumab is correlated with reduced serum dupilumab concentrations.</p>
      </sec>
      <sec id="article-144777.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms, Strengths, and Adult Dosage</bold>
</p>
        <p>The initial recommended dose of dupilumab comprises&#x000a0;2&#x000a0;SC injections at different injection sites, followed by&#x000a0;1 injection at various locations every&#x000a0;2 weeks or every&#x000a0;4 weeks, depending on the patient's age and weight.<xref ref-type="bibr" rid="article-144777.r22">[22]</xref>&#x000a0;Dupilumab is supplied as a pre-filled syringe containing 300 mg/2 mL of solution with a needle shield for single-dose use.<xref ref-type="bibr" rid="article-144777.r22">[22]</xref></p>
        <p>More recently,&#x000a0;2 large phase 3 trials, including adults with symptoms inadequately suppressed by topical medications commonly used to manage atopic dermatitis, demonstrated the role of dupilumab in treating the condition. Patients were treated with either a placebo or 300 mg dupilumab administered weekly or every&#x000a0;2 weeks over 16 weeks. A significant reduction of 75% in eczema area and severity index (EASI) was observed in patients on dupilumab in both weekly and 2-weekly interval dosing regimens.<xref ref-type="bibr" rid="article-144777.r22">[22]</xref>&#x000a0;The FDA-approved dosage of dupilumab for specific indications is listed below.</p>
        <p><bold>Atopic dermatitis:</bold>&#x000a0;The suggested initial dose of dupilumab is 600 mg (administered as&#x000a0;2 300 mg injections), followed by a subsequent maintenance dose of 300 mg every other week (Q2W).</p>
        <p><bold>Asthma:</bold>&#x000a0;The initial dose of dupilumab is 400 mg (administered as&#x000a0;2 200 mg injections), followed by a subsequent maintenance dose of 200 mg every&#x000a0;2 weeks (Q2W). The initial dosage for&#x000a0;moderate to severe atopic dermatitis or oral corticosteroid-dependent asthma is 600 mg (2 300 mg injections), followed by a subsequent dose of 300 mg every other week (Q2W).</p>
        <p><bold>Chronic rhinosinusitis with nasal polyposis:</bold>&#x000a0;The dosage of dupilumab for adult patients is 300 mg, given every other week (Q2W).</p>
        <p><bold>Eosinophilic esophagitis: </bold>300 mg of dupilumab weekly is the recommended dosage for patients weighing at least 40 kg and aged 12 or older.</p>
        <p><bold>Prurigo nodularis:</bold>&#x000a0;The recommended initial dose of dupilumab is 600 mg (2 300 mg injections), followed by a maintenance dose of 300 mg dupilumab given every other week (Q2W).<xref ref-type="bibr" rid="article-144777.r24">[24]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:</bold>&#x000a0;The manufacturer's labeling does not provide dosage adjustments for dupilumab, which has not been studied in this population.</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;The manufacturer's labeling does not provide dosage adjustments for dupilumab, which has not been studied in this population.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;It is unknown whether dupilumab use during pregnancy may cause harm to the fetus, including congenital defects or other adverse outcomes.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref>&#x000a0;Since IgG antibodies can cross transplacentally, the possibility of dupilumab's transmission from the mother to the fetus exists.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref>&#x000a0;Animal research studies have shown no adverse effects on the growth or development of offspring at birth or later after IL-4R alpha antibody injection.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref>&#x000a0;Several case reports in which dupilumab was either discontinued before conception or a few weeks after conception demonstrated no fetal harm.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref>&#x000a0;However, more research is required to analyze the harmful effect of dupilumab on a fetus when used continually during pregnancy.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;It is unknown whether dupilumab is excreted in breast milk or systemic absorption occurs after ingestion.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref>&#x000a0;The amount of dupilumab in breast milk is expected to be low, given its large size, and absorption is unlikely because it is destroyed in the infant's gastrointestinal tract.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref>&#x000a0;It is crucial to assess the importance of breast milk, along with the mother's medical indication and urgency for dupilumab use.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref></p>
        <p><bold>Pediatric patients:</bold> Dupilumab is an FDA-approved medication for moderate-to-severe atopic dermatitis in patients&#x000a0;6 months and older. It is also approved as an add-on maintenance treatment for moderate-to-severe asthma in pediatric patients aged&#x000a0;6&#x000a0;and older with oral corticosteroid dependence or presenting with an eosinophilic phenotype.<xref ref-type="bibr" rid="article-144777.r26">[26]</xref>&#x000a0;Additionally, dupilumab is approved for eosinophilic esophagitis in patients&#x000a0;weighing at least 40 kg (12 years or older). However, dupilumab is not FDA-approved for pediatric use in chronic rhinosinusitis with nasal polyposis or prurigo nodularis.</p>
        <p><bold>Geriatric patients:</bold> Analysis of 4 RCT studies on dupilumab has revealed that patients over 60 suffering from moderate-to-severe atopic dermatitis demonstrated a significant improvement in AD signs and symptoms. These results are comparable to those reported in patients under 60 years.<xref ref-type="bibr" rid="article-144777.r27">[27]</xref></p>
      </sec>
      <sec id="article-144777.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Although not common, dupilumab may cause serious adverse effects, including joint aches, eyelid swelling and inflammation, and allergic reactions such as shortness of breath and wheezing.<xref ref-type="bibr" rid="article-144777.r28">[28]</xref> However, the most common side effects noted in&#x000a0;atopic dermatitis patients on dupilumab include injection site reactions and eye and eyelid inflammation, including redness, swelling, itching, blurred vision, and cold sores in the mouth or lips.<xref ref-type="bibr" rid="article-144777.r28">[28]</xref><xref ref-type="bibr" rid="article-144777.r29">[29]</xref>&#x000a0;Most adverse events seen in clinical trials performed in patients aged 18 or above are mild or moderate in severity.<xref ref-type="bibr" rid="article-144777.r28">[28]</xref></p>
        <p>Nasopharyngitis and headaches have been reported more frequently among patients receiving dupilumab than those receiving a placebo.<xref ref-type="bibr" rid="article-144777.r28">[28]</xref>&#x000a0;Rare cases of epistaxis have been reported.<xref ref-type="bibr" rid="article-144777.r30">[30]</xref>&#x000a0;The occurrence of herpes viral infections has also been observed in some cases.<xref ref-type="bibr" rid="article-144777.r31">[31]</xref>&#x000a0;Dupilumab may induce various forms of arthropathy, enthesitis, and tendinopathy in certain highly atopic individuals by enhancing an IL-17-mediated peripheral spondyloarthritis/psoriatic arthritis pattern of inflammatory enthesitis.<xref ref-type="bibr" rid="article-144777.r32">[32]</xref> Further research is needed to establish a causal link and determine the exact mechanism.<xref ref-type="bibr" rid="article-144777.r32">[32]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Patients on warfarin may require monitoring of PT/INR and dose adjustment. Increased concentrations of certain cytokines (IL-4 and IL-13) can alter the function of CYP450 enzymes.<xref ref-type="bibr" rid="article-144777.r18">[18]</xref>&#x000a0;However, no significant drug interactions have been observed per the latest FDA label. Only significant DDI was observed for metoprolol and dupilumab, with an increase in AUC of 29%.&#x000a0;Administration of dupilumab with live vaccines is not recommended with dupilumab.<xref ref-type="bibr" rid="article-144777.r33">[33]</xref></p>
      </sec>
      <sec id="article-144777.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Several contraindications have been noted in the literature, some of which are listed below. However, insufficient scientific data or research-based evidence supports most of these contraindications. The only FDA-labeled contraindication to using dupilumab is hypersensitivity to any of its excipients.&#x000a0;Angioedema due to dupilumab has been reported.<xref ref-type="bibr" rid="article-144777.r34">[34]</xref><bold>&#x000a0;</bold>Dupilumab is contraindicated in patients with hamster protein hypersensitivity, as this drug is produced in Chinese hamster ovary cells.&#x000a0;Hypersensitivity reactions, including rash and allergic conjunctivitis, have occurred after dupilumab administration.<xref ref-type="bibr" rid="article-144777.r32">[32]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>
<bold>Acute bronchospasm, asthma, corticosteroid withdrawal, and status asthmaticus</bold>
</p>
        <p>While dupilumab is approved as an adjuvant or maintenance therapy to treat eosinophilic and glucocorticoid-dependent moderate-to-severe asthma, it should not be used by itself to treat episodes of asthma exacerbations or acute bronchospasm.<xref ref-type="bibr" rid="article-144777.r31">[31]</xref>&#x000a0;Patients with comorbid asthma who start dupilumab therapy for atopic dermatitis or chronic rhinosinusitis with nasal polyposis should be advised to stay on their asthma medications to prevent the onset of any adverse event.<xref ref-type="bibr" rid="article-144777.r31">[31]</xref>&#x000a0;However, a study by Rabe et al revealed that for patients on oral glucocorticoid therapy for moderate-to-severe asthma or acute asthma exacerbations, adding dupilumab not only led to an overall reduction in the glucocorticoid use but also alleviation of symptoms associated with acute asthmatic episodes or exacerbations over 24 weeks. The only notable but transient adverse effect was reversible eosinophilia in about 14% of the patients.<xref ref-type="bibr" rid="article-144777.r35">[35]</xref></p>
        <p>
<bold>Eosinophilic pneumonia and vasculitis</bold>
</p>
        <p>Rare cases of eosinophilic pneumonia and vasculitis consistent with eosinophilic granulomatosis with polyangiitis have been reported in asthmatic patients on dupilumab.<xref ref-type="bibr" rid="article-144777.r32">[32]</xref></p>
        <p>
<bold>Helminth infection</bold>
</p>
        <p>Patients with a preexisting helminthic infection should receive anti-helminthic therapy before starting dupilumab.<xref ref-type="bibr" rid="article-144777.r31">[31]</xref> However, if a patient becomes infected while receiving dupilumab and fails to respond to treatment with anti-helminthic medicine, dupilumab should be discontinued until the infection resolves.<xref ref-type="bibr" rid="article-144777.r31">[31]</xref>&#x000a0;Complete resolution of helminthic infection before starting dupilumab therapy for&#x000a0;atopic dermatitis is paramount and should take precedence.</p>
        <p>
<bold>Vaccination</bold>
</p>
        <p>Current FDA recommendations caution only against using live virus vaccines in dupilumab recipients. However, no concrete date is available on the ability of live vaccines to trigger an immune response.<xref ref-type="bibr" rid="article-144777.r32">[32]</xref>&#x000a0;It is suggested that all age-appropriate immunizations be completed before initiating dupilumab treatment.&#x000a0;Limited data are available regarding the coadministration of non-live vaccines with dupilumab.<xref ref-type="bibr" rid="article-144777.r31">[31]</xref></p>
      </sec>
      <sec id="article-144777.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Given the potential interaction of dupilumab with drugs that are substrates of the cytochrome P450 (CYP450), it is suggested to monitor those patients on medications like warfarin, which are also CYP450 substrates and can alter the activity of dupilumab.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref>&#x000a0;Interestingly, this may be uncertain speculation as a study conducted by Davis et al in 2018 failed to reveal any effect of dupilumab on the pharmacokinetics of CYP450 drugs.<xref ref-type="bibr" rid="article-144777.r31">[31]</xref></p>
        <p>Patients must be monitored for serious and sudden onset reactions when on dupilumab therapy. It is strongly advised to discontinue dupilumab if a systemic hypersensitivity reaction is noted.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref> Additionally, patients must report to their clinician any worsening eye symptoms leading to conjunctivitis and/or keratitis.&#x000a0;Patients with comorbid asthma must be monitored periodically to ensure that they continue their usual asthma treatment.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref></p>
        <p>Clinicians&#x000a0;are advised to monitor asthmatic patients with vasculitic rash, worsening pulmonary symptoms, cardiac complications, and neuropathy in the presence of eosinophilia, as dupilumab use in asthmatics may be associated with eosinophilic pneumonia or vasculitis.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref> Additionally, all healthcare team personnel must actively participate in patient counseling and provide access to resources and contacts if the need to contact the interprofessional team arises.<xref ref-type="bibr" rid="article-144777.r25">[25]</xref>&#x000a0;Social workers may not be effective in identifying reasons for lack of treatment adherence. Insurance delays can cause treatment delays. A follow-up by a nurse or medical assistant can help ensure timely medication and positive outcomes.</p>
      </sec>
      <sec id="article-144777.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Dupixent has no box warning, unlike the newer topical and oral Janus kinase (JAK) inhibitors used for treating atopic dermatitis.&#x000a0;Patients on JAK inhibitor treatment should be monitored closely for the onset of any infection.&#x000a0;The possible emergence of serious adverse events may result from the synergistic effects of JAK inhibitors with other immunomodulating agents, such as vitamin D, which also act on the JAK-STAT pathway.&#x000a0;No serious or frequent toxicity was reported.&#x000a0;Clinicians must be&#x000a0;careful when using dupilumab with substrates of CYP450, as it utilizes the same enzyme for its degradation. Rare cases of vasculitis and pneumonia are evident in patients using dupilumab and CYP450 substrates.<xref ref-type="bibr" rid="article-144777.r36">[36]</xref></p>
      </sec>
      <sec id="article-144777.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dupilumab is an effective and safe immunomodulating therapy for treating moderate-to-severe symptoms associated with atopic dermatitis, including itching, poor sleep quality, anxiety, and depression. Evidence from increasing trials suggests that the benefits of dupilumab far outweigh its side effects. Since no concrete literature-based evidence suggests that dupilumab is contraindicated during pregnancy or lactation, shared decision-making among healthcare team members and patients is paramount&#x000a0;for ensuring safe and effective treatment plans. Patients should receive significant education on their treatment options, including discussing the benefits and risks to maternal and fetal health, and that&#x000a0;patient values and preferences are considered. Consultation with an immunologist is required before initiating dupilumab for severe asthma. Moderate to severe atopic dermatitis is best managed in consultation with a dermatologist. Otorhinolaryngologist consultation is necessary for patients with&#x000a0;chronic rhinosinusitis with nasal polyposis.&#x000a0;Both pharmacists and nurses need easy and direct access to the prescriber so any patient concerns regarding dupilumab use can be addressed immediately. Communication among healthcare team members is pivotal to obtaining optimal therapeutic results for dupilumab use with minimal adverse events.</p>
      </sec>
      <sec id="article-144777.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144777&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144777">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/144777/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=144777">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-144777.s11">
        <title>References</title>
        <ref id="article-144777.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maloney</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Tegtmeyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Worswick</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>18</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">31603635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vangipuram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab for Moderate-to-Severe Atopic Dermatitis.</article-title>
            <source>Skin Therapy Lett</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">29091379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Napolitano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Guida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nocerino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fabbrocini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Patruno</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The emerging role of dupilumab in dermatological indications.</article-title>
            <source>Expert Opin Biol Ther</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1461</fpage>
            <page-range>1461-1471</page-range>
            <pub-id pub-id-type="pmid">33769900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seegr&#x000e4;ber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Srour</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Knop</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wollenberg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab for treatment of atopic dermatitis.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2018</year>
            <month>May</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>467</fpage>
            <page-range>467-474</page-range>
            <pub-id pub-id-type="pmid">29557246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Senner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seegr&#x000e4;ber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kendziora</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eicher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wollenberg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab for the treatment of adolescents with atopic dermatitis.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>641</fpage>
            <page-range>641-650</page-range>
            <pub-id pub-id-type="pmid">32720530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wenzel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maspero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pirozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Joish</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Eckert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Louis-Tisserand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teper</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting &#x003b2;2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Jul</month>
            <day>02</day>
            <volume>388</volume>
            <issue>10039</issue>
            <fpage>31</fpage>
            <page-range>31-44</page-range>
            <pub-id pub-id-type="pmid">27130691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Riordan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hanania</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Pavord</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Quirce</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chipps</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Thangavelu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Harel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jagerschmidt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maroni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pirozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruddy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>NMH</given-names>
              </name>
              <name>
                <surname>Teper</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>516</fpage>
            <page-range>516-526</page-range>
            <pub-id pub-id-type="pmid">31521831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holguin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cardet</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Diver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kellermeyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Khurana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Rigau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Subbarao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tonia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Adcock</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Bleecker</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Brightling</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boulet</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Cabana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chanez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Custovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Djukanovic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Frankem&#x000f6;lle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hamerlijnck</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jarjour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Konno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vitary</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.</article-title>
            <source>Eur Respir J</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">31558662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yosipovitch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mollanazar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kwatra</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Laws</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mannent</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Akinlade</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Staudinger</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Weinreich</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Malley</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.</article-title>
            <source>Nat Med</source>
            <year>2023</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>1180</fpage>
            <page-range>1180-1190</page-range>
            <pub-id pub-id-type="pmid">37142763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab for the treatment of prurigo nodularis: A systematic review.</article-title>
            <source>Front Immunol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1092685</fpage>
            <pub-id pub-id-type="pmid">36742321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nhu</surname>
                <given-names>QM</given-names>
              </name>
              <name>
                <surname>Aceves</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Current state of biologics in treating eosinophilic esophagitis.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>130</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-20</page-range>
            <pub-id pub-id-type="pmid">36243282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Horani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Chiles</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>First Therapeutic Approval for Eosinophilic Esophagitis.</article-title>
            <source>Gastroenterol Insights</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-244</page-range>
            <pub-id pub-id-type="pmid">35967984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aceves</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Dellon</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Greenhawt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Liacouras</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Spergel</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>130</volume>
            <issue>3</issue>
            <fpage>371</fpage>
            <page-range>371-378</page-range>
            <pub-id pub-id-type="pmid">36521784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulkarni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rohan</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Travers</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Serrao</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Efficacy of Dupilumab in Alopecia Areata.</article-title>
            <source>Am J Case Rep</source>
            <year>2022</year>
            <month>Jun</month>
            <day>21</day>
            <volume>23</volume>
            <fpage>e936488</fpage>
            <pub-id pub-id-type="pmid">35726185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Schaft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thijs</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>de Bruin-Weller</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Balak</surname>
                <given-names>DMW</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?</article-title>
            <source>Curr Opin Allergy Clin Immunol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>341</fpage>
            <page-range>341-349</page-range>
            <pub-id pub-id-type="pmid">31145194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Rabe</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Hanania</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Vogelmeier</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bafadhel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christenson</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Papi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Laws</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mannent</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Staudinger</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Mortensen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Akinlade</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Abdulai</surname>
                <given-names>RM</given-names>
              </name>
              <collab>BOREAS Investigators</collab>
            </person-group>
            <article-title>Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Jul</month>
            <day>20</day>
            <volume>389</volume>
            <issue>3</issue>
            <fpage>205</fpage>
            <page-range>205-214</page-range>
            <pub-id pub-id-type="pmid">37272521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.</article-title>
            <source>Front Immunol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>738907</fpage>
            <pub-id pub-id-type="pmid">34721404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Ippolito</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pisano</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis.</article-title>
            <source>P T</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>532</fpage>
            <page-range>532-535</page-range>
            <pub-id pub-id-type="pmid">30186024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hurdayal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brombacher</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Interleukin-4 Receptor Alpha: From Innate to Adaptive Immunity in Murine Models of Cutaneous Leishmaniasis.</article-title>
            <source>Front Immunol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>1354</fpage>
            <pub-id pub-id-type="pmid">29176972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harb</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chatila</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Dupilumab.</article-title>
            <source>Clin Exp Allergy</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-14</page-range>
            <pub-id pub-id-type="pmid">31505066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guttman-Yassky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bissonnette</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ungar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez-Fari&#x000f1;as</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ardeleanu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suprun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Estrada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Menter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>NMH</given-names>
              </name>
              <name>
                <surname>Pirozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>D Hamilton</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>143</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-172</page-range>
            <pub-id pub-id-type="pmid">30194992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jamgochian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pappert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cubeli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Psychosocial Burden Associated With and Effective Treatment Approach for Atopic Dermatitis: A Literature Review.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1046</fpage>
            <page-range>1046-1050</page-range>
            <pub-id pub-id-type="pmid">34636512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <chapter-title>Dupilumab</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>8</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31643386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holm</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Agner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab for prurigo nodularis: Case series and review of the literature.</article-title>
            <source>Dermatol Ther</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>e13222</fpage>
            <pub-id pub-id-type="pmid">31917498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bosma</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gerbens</surname>
                <given-names>LAA</given-names>
              </name>
              <name>
                <surname>Middelkamp-Hup</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Spuls</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>1089</fpage>
            <page-range>1089-1092</page-range>
            <pub-id pub-id-type="pmid">33969522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bacharier</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Maspero</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Katelaris</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Fiocchi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Gagnon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Mir</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sher</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Khokhar</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Deniz</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ruddy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laws</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Weinreich</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mannent</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hardin</surname>
                <given-names>M</given-names>
              </name>
              <collab>Liberty Asthma VOYAGE Investigators</collab>
            </person-group>
            <article-title>Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Dec</month>
            <day>09</day>
            <volume>385</volume>
            <issue>24</issue>
            <fpage>2230</fpage>
            <page-range>2230-2240</page-range>
            <pub-id pub-id-type="pmid">34879449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverberg</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Lynde</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Abuabara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patruno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Benedetto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>B&#x000e9;go-Le-Bagousse</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Khokhar</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Vakil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marco</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Levit</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Dupilumab Maintained in Adults &#x02265; 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2023</year>
            <month>May</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>469</fpage>
            <page-range>469-483</page-range>
            <pub-id pub-id-type="pmid">36808602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Tha&#x000e7;i</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bieber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rocklin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ming</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ardeleanu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Pirozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guttman-Yassky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez-Fari&#x000f1;as</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hager</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Radin</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Jul</month>
            <day>10</day>
            <volume>371</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-9</page-range>
            <pub-id pub-id-type="pmid">25006719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aszodi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thurau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seegr&#x000e4;ber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Bruin-Weller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wollenberg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of dupilumab-associated conjunctivitis in atopic dermatitis.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2019</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>488</fpage>
            <page-range>488-491</page-range>
            <pub-id pub-id-type="pmid">30873757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nitro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bulfamante</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rosso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Saibene</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Arnone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Felisati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pipolo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review.</article-title>
            <source>Acta Otorhinolaryngol Ital</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-204</page-range>
            <pub-id pub-id-type="pmid">35880360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tameez Ud Din</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Arshad</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tameez Ud Din</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Apr</month>
            <day>06</day>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>e7565</fpage>
            <pub-id pub-id-type="pmid">32382467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willsmore</surname>
                <given-names>ZN</given-names>
              </name>
              <name>
                <surname>Woolf</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kirkham</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Pink</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series.</article-title>
            <source>Br J Dermatol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>181</volume>
            <issue>5</issue>
            <fpage>1068</fpage>
            <page-range>1068-1070</page-range>
            <pub-id pub-id-type="pmid">31017658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez-Cabriales</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Constantinescu</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Murguia-Favela</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ramien</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>443</fpage>
            <page-range>443-455</page-range>
            <pub-id pub-id-type="pmid">34076879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fritz</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lacy</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Morrell</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Angioedema: A potential complication of dupilumab in atopic dermatitis.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>237</fpage>
            <page-range>237-238</page-range>
            <pub-id pub-id-type="pmid">33099796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabe</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brusselle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maspero</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Staudinger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pirozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Antoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruddy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akinlade</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>NMH</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Teper</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Jun</month>
            <day>28</day>
            <volume>378</volume>
            <issue>26</issue>
            <fpage>2475</fpage>
            <page-range>2475-2485</page-range>
            <pub-id pub-id-type="pmid">29782224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144777.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmariah</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Merola</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>427</fpage>
            <page-range>427-431</page-range>
            <pub-id pub-id-type="pmid">35679017</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
